<DOC>
	<DOCNO>NCT01235793</DOCNO>
	<brief_summary>The primary purpose study test dose temozolomide find target dose person tolerate . The part study determine helpful CNS lymphoma patient add temozolomide `` condition regimen '' prior stem cell transplantation . This research study design test investigational use temozolomide part condition regimen prior stem cell transplantation . This drug yet approve U.S. Food Drug Administration ( FDA ) use set stem cell transplantation lymphoma brain ( central nervous system CNS ) study used transplantation reasonable result .</brief_summary>
	<brief_title>The Addition Temozolomide Conditioning Autologous Transplantation Relapsed &amp; Refractory CNS Lymphoma</brief_title>
	<detailed_description>Currently standard care relapse refractory primary central nervous system ( CNS ) lymphoma . After high-dose methotrexate radiation therapy , best approach relapse disease undefined . Common practice regimen RBEAM condition regimen patient population prior transplantation . The RBEAM regimen include R ( rituximab ) , B ( BCNU ) , E ( etoposide ) , A ( Ara-C ( cytarabine ) ) M ( melphalan ) . In addition , dexamethasone include regimen although noted RBEAM mnemonic . However , melphalan use combination think much CNS penetration . Therefore , temozolomide , alkylating agent know penetrate CNS approve FDA brain tumor use evaluate study instead melphalan . The aim study determine effective safe dose temozolomide orally administer patient relapse primary CNS lymphoma 5 day precede autologous stem-cell transplantation . The hope condition regimen DRBEAT [ D ( dexamethasone ) ( R ( rituximab ) , B ( BCNU ) , E ( etoposide ) , A ( Ara-C ( cytarabine ) ) T ( temozolomide ) ] significantly improve survival patient relapse CNS lymphoma .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>1 . Patients ≥ 18 year age ≤ 75 year age 2 . Patients must Central Nervous System ( CNS ) involvement mature Bcell nonHodgkin 's Lymphoma , ( WHO criteria ) 3 . Patients must meet one criterion : Patients achieve complete response ( CR ) partial response ( PR ) initial therapy Central Nervous System ( CNS ) Bcell lymphoma , OR Patients relapse progressed disease follow therapy CNS Bcell lymphoma achieve subsequent CR PR follow salvage chemotherapy , OR Patients initially refractory therapy CNS Bcell lymphoma achieve CR PR follow salvage chemotherapy regimen , OR Patients develop CNS relapse systemic Bcell NonHodgkin 's lymphoma , evidence chemotherapy sensitive lymphoma . 4 . Patients fit autologous stem cell transplantation 5 . Patients able understand willing sign write informed consent document 1 . Patients whose life expectancy severely limited disease malignancy 2 . Karnofsky Performance Score &lt; 60 3 . Patients pregnant breastfeed 4 . Patients HIV seropositive 5 . Patients uncontrolled infection ( presume document ) progression appropriate therapy great one month 6 . Patients symptomatic coronary artery disease , uncontrolled congestive heart failure . Left Ventricular Ejection Fraction require measure , however measure , patient exclude ejection fraction &lt; 30 % 7 . Patients require supplementary continuous oxygen . 8 . Patients clinical laboratory evidence liver disease evaluate cause liver disease , clinical severity term liver function histology , degree portal hypertension . Patients follow liver function abnormality exclude 1 . Fulminant liver failure 2 . Cirrhosis evidence portal hypertension bridge fibrosis 3 . Alcoholic hepatitis 4 . Esophageal varix 5 . A history bleed esophageal varix 6 . Hepatic encephalopathy 7 . Uncorrectable hepatic synthetic dysfunction evidence prolongation prothrombin time 8 . Ascites related portal hypertension 9 . Chronic viral hepatitis total serum bilirubin &gt; 3 mg/dL 10 . Symptomatic biliary disease 9 . Patients nonBcell lymphomas brain tumor lymphomas Excluded study . NonBcell lymphomas include : Tcell lymphoma , natural killer ( NK ) cell lymphoma , Hodgkin lymphomas 10 . Patients insufficient number stem cell ( &lt; 2 X 106/kg ) collect</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>Primary Central Nervous System B-cell Lymphoma</keyword>
	<keyword>Autologous Stem Cell Transplant</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>B-Cell Lymphoma</keyword>
	<keyword>RBEAM</keyword>
	<keyword>Conditioning Regimen</keyword>
</DOC>